Why we filed an MHRA Borderline Advice Form before launch

What an MHRA Borderline Advice Form is

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK's medicines regulator. One of its responsibilities is determining the borderline between medicines and other products — including food supplements, cosmetics, and medical devices.

Some products sit clearly on one side of the line (an aspirin tablet is unambiguously a medicine; a vitamin C tablet is unambiguously a food supplement). Many products — particularly herbal preparations, multi-ingredient supplements, and products with potential health claims — sit closer to the line.

The MHRA Borderline Advice Form is the formal mechanism a brand can use to ask the MHRA, in advance: "If we sell this product as a food supplement, will you consider it a food supplement or an unlicensed medicine?" The form is free. The MHRA responds in writing, typically within 12 weeks.

Most UK supplement brands skip this step. We filed it for The Barakah Pill pre-launch.

Why we did it

Three reasons:

1. Risk management. If a brand sells a product as a food supplement and the MHRA later reclassifies it as an unlicensed medicine, the consequences are serious: product recall, MHRA enforcement, marketing-authorisation requirement that takes 2-5 years and costs millions, and potential criminal proceedings against the brand officers responsible. Filing the Borderline Advice Form pre-launch is a free insurance policy against this scenario.

2. Documentation of due diligence. Even if the MHRA's advice isn't legally binding (it isn't — they reserve the right to change classification), an MHRA Borderline opinion in our files is meaningful documentation of our pre-launch due diligence. If ever questioned, we can show we asked the regulator before we launched.

3. A reality-check on our copy. The Borderline Advice Form requires us to submit our intended label, claims, marketing copy, and ingredient deck. The MHRA reviews the entire package. If our marketing language drifted into medicinal-claim territory, the MHRA's response would flag it. We get a free expert review of our positioning by the regulator who would otherwise be the one enforcing it.

What we submitted

Our Borderline Advice Form submission included:

- The full label artwork for The Barakah Pill - The full product page copy - The full ingredient deck with doses - Marketing materials including ad copy drafts - A description of our intended sales channels (own e-commerce; no third-party medical claim sites) - A statement of our self-classification as a food supplement under the relevant UK food law

The MHRA reviews up to four products per single submission. We filed one product (The Barakah Pill) and have left room in case we file follow-on products later in 2026.

What we expect the MHRA to say

Based on the formulation and our copy posture, we expect the MHRA to confirm the product as a food supplement, not a medicine. The reasoning:

- Ingredient doses are at standard supplement levels — no ingredient is at a pharmacologically-active dose typical of a medicine - The capsule format is consistent with supplement category, not pharmaceutical - The labelling is supplement-compliant — mandatory FSA phrases ("Food supplement," "Do not exceed the stated recommended daily dose," "Should not be used as a substitute for a varied diet") - The marketing copy is non-medicinal — we describe ingredients, cite research, use authorised health claims with exact wording, and explicitly state the product does not treat, cure, or prevent any condition - The packaging is supplement-aesthetic — apothecary glass bottle, no medicinal-looking pharmacy-style packaging that would suggest medicine category

If the MHRA flags anything, we will address it before launch. If they confirm the supplement classification, we proceed with launch. Either way, the answer is in writing.

What this means for buyers

If you're buying The Barakah Pill, the MHRA Borderline Advice on file means:

- The MHRA has reviewed our product and our marketing claims and confirmed (we expect) the food supplement classification - The labelling and claims you read on our packaging and website have been reviewed by the UK regulator who would otherwise enforce against us - The risk of mid-market reclassification — which could disrupt your supply or trigger product recall — is materially lower

For a premium daily supplement, this matters. The hidden risk of buying from a brand that hasn't done this work is that one MHRA enforcement action can shut down the brand overnight. Filing the form is cheap insurance.

What this doesn't mean

Filing the Borderline Advice Form is not the same as MHRA approval or endorsement of the product. The MHRA doesn't endorse food supplements. The Borderline Advice is purely a classification answer — "this is a food supplement, not a medicine" — and doesn't extend to whether the product is effective, safe at our specific doses (covered by FSA risk assessments separately), or worth the price.

The Borderline Advice is a regulatory hygiene step, not a quality stamp.

What other regulators we're working with

The full UK regulatory landscape for The Barakah Pill includes:

- MHRA (Medicines and Healthcare products Regulatory Agency) — Borderline Advice Form, this article - FSA (Food Standards Agency) — food supplement compliance, novel food register monitoring (Ashwagandha CoT review remains active; Tongkat Ali removed from v3.0 formulation), allergen labelling - ASA (Advertising Standards Authority) — pre-launch ad copy review through ASA Copy Advice (free service) - HFA (Halal Food Authority) — own-brand halal certification (in final review) - ICO (Information Commissioner's Office) — registration as a data controller, GDPR compliance - HMRC — VAT registration; supplement capsules are standard-rated VAT by default per HMRC guidance - Companies House — incorporation, confirmation statements, director appointments

Each one has been engaged pre-launch, either directly (MHRA, ASA, ICO) or through the relevant industry processes (HFA, HMRC, Companies House). This is the kind of pre-launch work most consumer brands don't talk about. We think it should be talked about.

When we expect the MHRA response

The MHRA's published response window is typically 6-12 weeks for a Borderline Advice Form. We filed in early 2026; expect response by mid-2026 (broadly aligned with our launch timeline).

The response will be published on /halal-promise/ when it lands. The HFA cert will follow.

---

Sources: MHRA Borderline Advice guidance (gov.uk/guidance/borderline-products-products-on-the-borderline-with-medicines); Human Medicines Regulations 2012; ASA CAP Code Section 13 (food supplements); FSA food supplement guidance.